{"drugs":["Diphtheria, Tetanus, Pertussis, and Poliovirus Vaccine","Kinrix","Quadracel"],"mono":{"0":{"id":"928555-s-0","title":"Generic Names","mono":"Diphtheria, Tetanus, Pertussis, and Poliovirus Vaccine"},"1":{"id":"928555-s-1","title":"Dosing and Indications","sub":{"1":{"id":"928555-s-1-5","title":"Pediatric Dosing","mono":"<b>Diphtheria, pertussis and tetanus triple and polio vaccination:<\/b> (4 to 6 years) A single 0.5-mL dose IM in the deltoid muscle (preferred site) "},"3":{"id":"928555-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Diphtheria, pertussis and tetanus triple and polio vaccination<br\/>"}}},"3":{"id":"928555-s-3","title":"Contraindications\/Warnings","sub":[{"id":"928555-s-3-9","title":"Contraindications","mono":"<ul><li>Encephalopathy (eg, coma, decreased level of consciousness, prolonged seizures) within 7 days of a previous dose of pertussis-containing vaccine and not attributable to other causes<\/li><li>Progressive neurologic disorder (eg, infantile spasms, uncontrolled epilepsy, progressive encephalopathy); defer vaccination until neurologic status is stabilized<\/li><li>Severe allergic reaction (eg, anaphylaxis) to any component of the product, including neomycin and polymyxin B in Kinrix(R), or to a previous dose of any diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, or inactivated poliovirus vaccine<\/li><\/ul>"},{"id":"928555-s-3-10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- Collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours of administration of any prior pertussis-containing vaccine; evaluate benefit\/risk prior to administration<\/li><li>-- Syncope that may be accompanied by transient neurological signs (ie, visual disturbance, paresthesia, tonic-clonic limb movements) may occur<\/li><li>Immunologic:<\/li><li>-- Anaphylactic or acute hypersensitivity reaction may occur<\/li><li>-- Reduced immune response to vaccine may occur in immunocompromised patients including those receiving immunosuppressive therapy (eg, corticosteroid, antimetabolite, alkylating, or cytotoxic medications; radiation)<\/li><li>-- Latex allergy; tip cap of prefilled syringes may contain natural latex rubber<\/li><li>-- Arthus-type hypersensitivity reaction after a previous tetanus toxoid-containing vaccine; defer vaccination until at least 10 years since last tetanus toxoid vaccine<\/li><li>Neurologic:<\/li><li>-- Seizure, with or without fever, occurring within 3 days of administration of any prior pertussis-containing vaccine; evaluate benefit\/risk prior to administration<\/li><li>-- Guillain-Barre syndrome within 6 weeks of administration of any prior tetanus toxoid-containing vaccine; evaluate benefit\/risk prior to administration<\/li><li>Other:<\/li><li>-- Fever of 40.5 degrees C (105 degrees F) or higher within 48 hours of administration of any prior pertussis-containing vaccine and unrelated to other causes; evaluate benefit\/risk prior to administration<\/li><li>-- Crying that is persistent and inconsolable for 3 hours or more and occurring within 48 hours of administration of any prior pertussis-containing vaccine; evaluate benefit\/risk prior to administration<\/li><li>-- Moderate or severe acute illness with or without fever; defer vaccination unless the benefit of protection outweighs the risk of an adverse reaction<\/li><li>-- Children with high seizure risk; consider prophylactic antipyretics with administration and for 24 hours after vaccination to reduce postvaccination fever<\/li><li>-- Can be administered during pregnancy if there is a risk for exposure to wild-type poliovirus infection<\/li><li>-- Revaccination in patients with unknown vaccination history may require serologic testing; an increased rate of adverse events may occur after the fourth and fifth DTaP dose<\/li><\/ul>"},{"id":"928555-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"928555-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"928555-s-4","title":"Drug Interactions","sub":{"1":{"id":"928555-s-4-14","title":"Major","mono":"<ul>Cyclosporine (theoretical)<\/ul>"},"2":{"id":"928555-s-4-15","title":"Moderate","mono":"<ul><li>Chloramphenicol (probable)<\/li><li>Meningococcal Vaccine, Tetanus Toxoid Conjugate Quadrivalent (established)<\/li><\/ul>"}}},"5":{"id":"928555-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Erythema at injection site (36.6% to 59.1%), Injection site pain (57% to 77.4%), Swelling at injection site (26% to 40.2%)<\/li><li><b>Gastrointestinal:<\/b>Loss of appetite (15.5%)<\/li><li><b>Musculoskeletal:<\/b>Myalgia (53.8%)<\/li><li><b>Neurologic:<\/b>Headache (15.6%), Somnolence (19.1%)<\/li><li><b>Other:<\/b>Fever (6% to 16%), Increase in circumference, Limb (36% to 68.1%), Malaise (35%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Syncope<\/li><li><b>Endocrine metabolic:<\/b>Dehydration, Hypernatremia<\/li><li><b>Gastrointestinal:<\/b>Gastroenteritis<\/li><\/ul>"},"6":{"id":"928555-s-6","title":"Drug Name Info","sub":[{"id":"928555-s-6-17","title":"US Trade Names","mono":"<ul><li>Kinrix<\/li><li>Quadracel<\/li><\/ul>"},{"id":"928555-s-6-18","title":"Synonyms","mono":"<ul><li>DTaP-IPV - Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine<\/li><li>DTaP and Polio Vaccine<\/li><li>Diphtheria Toxoid, Adsorbed; Pertussis Vaccine, Acellular; Tetanus Toxoid; and Poliovirus Vaccine, Inactivated<\/li><\/ul>"},{"id":"928555-s-6-19","title":"Class","mono":"Vaccine<br\/>"},{"id":"928555-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},{"id":"928555-s-6-21","title":"Generic Availability","mono":"No<br\/>"}]},"7":{"id":"928555-s-7","title":"Mechanism Of Action","mono":"<ul><li>Diphtheria: Following IM injection, diphtheria toxoid induces the formation of neutralizing antibodies to diphtheria toxin.<\/li><li>Tetanus: Following IM injection, tetanus toxoid induces the formation of neutralizing antibodies to tetanus toxin.<\/li><li>Pertussis: Following IM injection, acellular pertussis vaccine induces the formation of several antibodies thought to be clinically protective. The levels of antibody necessary for protection have not been determined.<\/li><li>Inactivated Poliovirus Vaccine (IPV): Following IM injection, IPV induces the production of neutralizing antibodies against each poliovirus serotype correlating with protection against poliomyelitis.<\/li><\/ul>"},"9":{"id":"928555-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>For IM use only; do not administer IV, intradermally, or subcutaneously.<br\/><\/li><li><b>Intramuscular<\/b><br\/><ul><li>(Quadracel(TM)) Shake vial well to create uniform, white, cloudy suspension prior to aseptic withdrawal of dose<\/li><li>(Kinrix(R)) Shake vial or prefilled syringe vigorously to get a homogenous, turbid, white suspension; do not use vial if resuspension does not occur<\/li><li>(Kinrix(R)) Vial or prefilled syringe are intended for single use only; a sterile needle is required when using the prefilled syringes (not supplied)<\/li><li>Deltoid muscle is preferred site of injection<\/li><li>Use separate syringes (do not mix) when administering concomitantly with other vaccines<\/li><li>(Kinrix(R)) Tip cap of the prefilled syringes may contain natural rubber latex; vial stopper and plungers are not made with natural rubber latex<\/li><\/ul><\/li><\/ul>"},"10":{"id":"928555-s-10","title":"Monitoring","mono":"No specific monitoring has been determined.<br\/>"},"11":{"id":"928555-s-11","title":"How Supplied","mono":"<ul><li><b>Kinrix<\/b><br\/>Intramuscular Suspension: (Diphtheria Toxoid, Adsorbed - Pertussis Vaccine, Acellular - Poliovirus Vaccine, Inactivated - Tetanus Toxoid) 25 Lf U\/0.5 ML-58 MCG\/0.5 ML-80 D Antigen U\/0.5 ML-10 Lf U\/0.5 ML<br\/><\/li><li><b>Quadracel<\/b><br\/>Intramuscular Suspension: (Diphtheria Toxoid, Adsorbed - Pertussis Vaccine, Acellular - Poliovirus Vaccine, Inactivated - Tetanus Toxoid) 15 Lf U\/0.5 ML-48 MCG\/0.5 ML-80 D Antigen U\/0.5 ML-5 Lf U\/0.5 ML<br\/><\/li><\/ul>"},"13":{"id":"928555-s-13","title":"Clinical Teaching","mono":"<ul><li>Instruct caregiver to report any of the following symptoms: a temperature of 40.5 degrees C (105 degrees F) or higher; persistent, inconsolable crying lasting 3 hours or more; a collapse or shock-like state (hypotonic, hyporesponsive); or a seizure with or without fever.<\/li><li>Side effects may include injection site reactions (pain, erythema, swelling), drowsiness, fever, loss of appetite, myalgia, malaise, and headache.<\/li><\/ul>"}}}